View in EDS

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Saved in:
Bibliographic Details
Title: 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Authors: Pivot, Xavier1 xavier.pivot@univ-fcomte.fr, Romieu, Gilles2, Debled, Marc3, Pierga, Jean-Yves4, Kerbrat, Pierre5, Bachelot, Thomas6, Lortholary, Alain7, Espié, Marc8, Fumoleau, Pierre9, Serin, Daniel10, Jacquin, Jean-Philippe11, Jouannaud, Christelle12, Rios, Maria13, Abadie-Lacourtoisie, Sophie14, Tubiana-Mathieu, Nicole15, Cany, Laurent16, Catala, Stéphanie17, Khayat, David18, Pauporté, Iris19, Kramar, Andrew20
Source: Lancet Oncology. Jul2013, Vol. 14 Issue 8, p741-748. 8p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(13)70225-0